Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.

Biotechnology

Health Care

Life Sciences

Therapeutics

Alpha-9 Oncology

David Hirsch

Pau-Lin Ngen

Stephen Mitchener

Julie Rousseau

Matthias Jaffe

Alison Fleming

The Leadership Team at Alpha-9 Oncology drives the strategic vision and operational execution of the company's mission to develop innovative radiopharmaceuticals for cancer treatment. Comprising the CEO, COO, CFO, and Chief Business Officer, this team leverages their expertise to oversee clinical development, regulatory compliance, financial management, and commercial strategy, ensuring alignment across all functions to advance the company’s robust pipeline and enhance patient outcomes.

Leadership Team

Scientific Research Team

Leadership Team

About

Team members

Other teams at Alpha-9 Oncology

Scientific Research Team